Shots:

• Takeda enters into a licensing agreement with Curadev for its Stimulator of Interferon Genes (STING) agonist/ CRD5500 and its associated patents
• The focus of the agreement is to develop immuno-oncology targets- providing one day deliver transformational benefit to patients. Additionally- out-licenses its IP portfolio to Endo- Medivation & Roche
• Curadev’s CRD5500 is a sting agonist amenable to bioconjugation as an ADC targeting anti-PD-L1/anti-CTLA4/IDO-TDOi- activating human STING variants to shrink tumors and successfully conjugated with trastuzumab

Ref: PRNewsWire | Image:Takeda